Duffner moves to PacificHealth CEO
This article was originally published in The Tan Sheet
Executive Summary
Fred Duffner, president of the Matawan, N.J., nutritional products firm, succeeds Jason Ash as chief executive officer, PacificHealth announced Aug. 31. Duffner joined PacificHealth Laboratories as senior VP of sales in August 2008 and became president in January (1"The Tan Sheet" Feb. 22, 2010). In a release, Duffner said PacificHealth has made progress refocusing on its core sports nutrition brands and trimming expenses
You may also be interested in...
People In Brief
Former FDA commissioner Hayes dies: Arthur Hull Hayes Jr., who led FDA from April 1981 through September 1983 and was a nationally known professor of clinical pharmacology, died on Feb. 11, 2010, from complications caused by a chronic illness, according to an obituary published by Munson-Lovetere Funeral Homes. He was 76. After being appointed FDA commissioner by President Ronald Reagan, Hayes' directed FDA's response to the Tylenol tampering in 1982, called for a voluntary moratorium on direct-to-consumer advertising of prescription medicines and weathered criticism on the FDA's approval of the sweetener aspartame. He earned a Rhodes Scholar degree in philosophy, politics and economics in 1957 before studying medicine, serving in Army Medical Corps from 1965-1967 and teaching medicine and pharmacy at Cornell and Pennsylvania State University before moving to FDA, and later was provost and dean at New York Medical College. According to FDA's Web site, in 1986 Hayes shifted to executive positions in the pharmaceutical industry, served on the editorial boards of Clinical Pharmacology and Therapeutics, Rational Drug Therapy and the Journal of Clinical Pharmacology, and was president of the American Society of Clinical Pharmacology and Therapeutics and the U.S. Pharmacopoeia. He retired in 2005, five years after founding MediScience Associates consultants, part of Nelson Communications Inc
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.